Pluses and minuses of the weight-loss drug bonanza
November 18, 2025
437
12
2.75%
Search the Record
IndexedEvery word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
Reuters Episodes Around November 18, 2025
See what was published immediately before and after this episode.
33:37Now PlayingPluses and minuses of the weight-loss drug bonanza
YouTube Description
as posted by the channelObesity treatments made by Novo Nordisk () and Eli Lilly have spawned () a healthcare revolution () , with sales set to hit $150 bln by 2031. In this episode of The Big View, Peter Thal Larsen talks to Breakingviews Associate Editor Aimee Donnellan about their origins and their impact.
Visit the Thomson Reuters Privacy Statement () for information on our privacy and data protection practices. You may also visit megaphone.fm/adchoices () to optout of targeted advertising.
Learn more about your ad choices. Visit megaphone.fm/adchoices ()
Guests & Subjects Covered
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.